WO2013020024A3 - Maleimide compounds and methods of treatment - Google Patents

Maleimide compounds and methods of treatment Download PDF

Info

Publication number
WO2013020024A3
WO2013020024A3 PCT/US2012/049470 US2012049470W WO2013020024A3 WO 2013020024 A3 WO2013020024 A3 WO 2013020024A3 US 2012049470 W US2012049470 W US 2012049470W WO 2013020024 A3 WO2013020024 A3 WO 2013020024A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
methods
maleimide compounds
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/US2012/049470
Other languages
French (fr)
Other versions
WO2013020024A2 (en
Inventor
Sharon Shacham
Eran SHACHAM
Yael Marantz
Ed Roberts
Michael Kauffman
Vincent P. SANDANAYAKA
Sharon Shechter
Original Assignee
Karyopharm Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics, Inc. filed Critical Karyopharm Therapeutics, Inc.
Publication of WO2013020024A2 publication Critical patent/WO2013020024A2/en
Publication of WO2013020024A3 publication Critical patent/WO2013020024A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein R, A and B are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
PCT/US2012/049470 2011-08-03 2012-08-03 Maleimide compounds and methods of treatment WO2013020024A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161514634P 2011-08-03 2011-08-03
US61/514,634 2011-08-03

Publications (2)

Publication Number Publication Date
WO2013020024A2 WO2013020024A2 (en) 2013-02-07
WO2013020024A3 true WO2013020024A3 (en) 2013-06-13

Family

ID=46642654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/049470 WO2013020024A2 (en) 2011-08-03 2012-08-03 Maleimide compounds and methods of treatment

Country Status (1)

Country Link
WO (1) WO2013020024A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106083827B (en) 2011-07-29 2019-09-17 卡尔约药物治疗公司 Core transport regulator containing hydrazides and application thereof
CN104428295B (en) 2012-05-09 2017-08-08 卡尔约药物治疗公司 Nuclear translocation conditioning agent and its application
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
US9738624B2 (en) 2013-06-21 2017-08-22 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US9861615B2 (en) * 2013-11-28 2018-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of beta-thalassemias
EA201790384A1 (en) 2014-08-15 2017-08-31 Кариофарм Терапевтикс, Инк. POLYMORPHES OF SILINEXOR
WO2016090355A2 (en) * 2014-12-05 2016-06-09 Massachusetts Institute Of Technology Catechol-rich polymers from n-substituted maleimides
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US11065230B2 (en) 2016-09-16 2021-07-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040113A2 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Phosphatase inhibitors
WO1997038983A1 (en) * 1996-04-12 1997-10-23 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
US20030032625A1 (en) * 2001-03-29 2003-02-13 Topo Target Aps Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors
US20050014803A1 (en) * 2000-05-11 2005-01-20 Consejo Superior De Investigaciones Cientificas, A Spain Corporation Enzyme inhibitors
US20070203236A1 (en) * 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
WO2008027912A2 (en) * 2006-08-28 2008-03-06 Dan Theodorescu Prediction of an agent's or agents' activity across different cells and tissue types
US20080275057A1 (en) * 2007-04-11 2008-11-06 Canbas Co., Ltd. Compounds with anti-cancer activity
WO2009151920A2 (en) * 2008-06-11 2009-12-17 Fred Hutchinson Cancer Research Center Hepsin inhibitors
WO2010114921A1 (en) * 2009-04-02 2010-10-07 Burnham Institute For Medical Research Eph receptor ligands and methods of use
WO2011003191A1 (en) * 2009-07-07 2011-01-13 Ottawa Hospital Research Institute Compositions and methods for enhancing virus efficacy
WO2011094708A2 (en) * 2010-01-29 2011-08-04 Dana-Farber Cancer Institute, Inc Small molecules for the modulation of mcl-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040113A2 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Phosphatase inhibitors
WO1997038983A1 (en) * 1996-04-12 1997-10-23 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
US20050014803A1 (en) * 2000-05-11 2005-01-20 Consejo Superior De Investigaciones Cientificas, A Spain Corporation Enzyme inhibitors
US20030032625A1 (en) * 2001-03-29 2003-02-13 Topo Target Aps Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors
US20070203236A1 (en) * 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
WO2008027912A2 (en) * 2006-08-28 2008-03-06 Dan Theodorescu Prediction of an agent's or agents' activity across different cells and tissue types
US20080275057A1 (en) * 2007-04-11 2008-11-06 Canbas Co., Ltd. Compounds with anti-cancer activity
WO2009151920A2 (en) * 2008-06-11 2009-12-17 Fred Hutchinson Cancer Research Center Hepsin inhibitors
WO2010114921A1 (en) * 2009-04-02 2010-10-07 Burnham Institute For Medical Research Eph receptor ligands and methods of use
WO2011003191A1 (en) * 2009-07-07 2011-01-13 Ottawa Hospital Research Institute Compositions and methods for enhancing virus efficacy
WO2011094708A2 (en) * 2010-01-29 2011-08-04 Dana-Farber Cancer Institute, Inc Small molecules for the modulation of mcl-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
COONEY D A ET AL: "MALEIMIDE BIOCHEMICAL PHARMACOLOGIC AND TOXICOLOGIC STUDIES INTERACTION WITH L ASPARAGINASE METABOLISM", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 27, no. 2, 1 January 1978 (1978-01-01), pages 151 - 166, XP002413425, ISSN: 0006-2952, DOI: 10.1016/0006-2952(78)90295-2 *
DEARMOND PATRICK D ET AL: "Discovery of Novel Cyclophilin A Ligands Using an H/D Exchange- and Mass Spectrometry-Based Strategy", JOURNAL OF BIOMOLECULAR SCREENING, October 2010 (2010-10-01), pages 1 - 21, XP002686097, ISSN: 1087-0571, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197229/pdf/nihms327558.pdf> [retrieved on 20121029] *
HAHN M A ET AL: "Pharmacology of 3,5-diamino-1,24-triazole (guanazole). 1. Antitumor activity of guanazole", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, vol. 48, no. 3, 1 March 1972 (1972-03-01), pages 783 - 790, XP008157634, ISSN: 0027-8874, DOI: 10.1093/JNCI/48.3.783 *
JHA A ET AL: "Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 20, no. 5, 1 March 2010 (2010-03-01), pages 1510 - 1515, XP026911292, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2010.01.098 *
KAU T R ET AL: "A CHEMICAL GENETIC SCREEN IDENTIFIES INHIBITORS OF REGULATED NUCLEAR EXPORT OF A FORKHEAD TRANSCRIPTION FACTOR IN PTEN-DEFICIENT TUMOR CELLS", CANCER CELL, CELL PRESS, US, vol. 4, no. 6, 1 December 2003 (2003-12-01), pages 463 - 476, XP008037524, ISSN: 1535-6108, DOI: 10.1016/S1535-6108(03)00303-9 *
LAUREN MONOVICH ET AL: "Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - GENE REGULATORY MECHANISMS, vol. 1789, no. 5, 1 May 2009 (2009-05-01), pages 422 - 431, XP055042123, ISSN: 1874-9399, DOI: 10.1016/j.bbagrm.2009.04.001 *
M. SORTINO ET AL: "Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 19, no. 9, 1 May 2011 (2011-05-01), pages 2823 - 2834, XP055042448, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2011.03.038 *
NICOLAS MATUSZAK ET AL: "Dual inhibition of MAGL and type II topoisomerase by-phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 45, no. 3, 11 November 2011 (2011-11-11), pages 263 - 271, XP028440380, ISSN: 0928-0987, DOI: 10.1016/J.EJPS.2011.11.011 *
SUZUKI T ET AL: "Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 20, no. 3, 1 February 2010 (2010-02-01), pages 1124 - 1127, XP026861882, ISSN: 0960-894X *
YUNES JOSE A ET AL: "Antiproliferative Effects of a Series of Cyclic Imides on Primary Endothelial Cells and a Leukemia Cell Line", vol. 63, no. 9-10, 1 September 2008 (2008-09-01), pages 675 - 680, XP008157636, ISSN: 0939-5075, Retrieved from the Internet <URL:http://www.znaturforsch.com/rc/s63c0675.pdf> [retrieved on 20121029] *

Also Published As

Publication number Publication date
WO2013020024A2 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
WO2013019561A8 (en) Nuclear transport modulators and uses thereof
EP4234545A3 (en) Hydrazide containing nuclear transport modulators and uses thereof
WO2013020024A3 (en) Maleimide compounds and methods of treatment
PH12017501426A1 (en) Derivatives of betulin
EA201290632A1 (en) DERIVATIVES OF BETULINA
MX2014001595A (en) Indazole compounds, compositions and methods of use.
MX2013007336A (en) Bi-heteroaryl compounds as vps34 inhibitors.
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
WO2012019426A8 (en) Phthalazinone derivative, and preparation method and pharmaceutical use thereof
WO2012019430A8 (en) Phthalazinone derivative, and preparation method and pharmaceutical use thereof
MX2015003594A (en) Therapeutic or prophylactic agent for tumor lysis syndrome.
WO2014036502A3 (en) Tetracycline compounds
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
IN2014CN04449A (en)
WO2013177349A3 (en) Quinazolinediones as tankyrase inhibitors
WO2011123536A8 (en) Polycyclic tetracycline compounds
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2010129057A3 (en) Tetracycline compounds
MX2014003803A (en) Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease.
WO2012118308A3 (en) Composition for preventing and treating cardiovascular diseases, containing pyrazole derivative
NZ707308A (en) Malononitrile compounds for controlling animal pests
PH12014502066A1 (en) Triazinone compound and t-type calcium channel inhibitor
MX2015007568A (en) Malononitrile compounds for controlling animal pests.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12745980

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12745980

Country of ref document: EP

Kind code of ref document: A2